Intravitreal corticosteroid MWS 2012 Han.ppt (Read-Only)
Intravitreal corticosteroid MWS 2012 Han.ppt (Read-Only)
Intravitreal corticosteroid MWS 2012 Han.ppt (Read-Only)
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
12/12/11<br />
1 month after 6 Lucentis<br />
injections, VA 20/125<br />
7/12/11 OCT OD<br />
37<br />
<strong>Intravitreal</strong> <strong>corticosteroid</strong><br />
therapy<br />
Ø IOP and cataract are downsides<br />
Ø Probably second line to ranibizumab<br />
for DME and RVO<br />
Ø A viable option for DME in<br />
pseudophakes: less frequent<br />
injections, IOP control easier with<br />
some modalities vs. others<br />
Ø Sustained release devices show<br />
promise 38<br />
RVO and ranibizumab: CRUISE<br />
and BRAVO studies<br />
(references)<br />
Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary<br />
end point results of a phase III study.<br />
Campochiaro PA.,et al.Ophthalmology. 117(6):1102-1112, 2010.<br />
Ranibizumab for macular edema following central retinal vein occlusion: six-month primary<br />
end point results of a phase III study.<br />
Brown DM, et al. Ophthalmology. 117(6):1124-1133.e1, 2010.<br />
39<br />
40<br />
10
Change language